Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers t

ADC Therapeutics NYSE: ADCT reported second-quarter 2026 net product revenue of $18.6 million for ZY

ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consen

On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earn

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.11) per share which beat the analyst c

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 millio

LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-s

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin

LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-s

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamabFull data

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views.

U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.6

U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.6

Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street ana

ADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III

RBC Capital analyst Leonid Timashev downgrades ADC Therapeutics (NYSE:ADCT) from Outperform to Se

ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse ev

ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study

Shares of PVH fell 21.42% in pre-market trading even after strong Q1. Gainers include CXApp, TaoWeav

ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcr

Company to host conference call today at 4:30 p.m. EDTLAUSANNE, Switzerland, June 3, 2026 /PRNewswir

Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswi

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers f

RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy a

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.13) per share which beat the analyst c

HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy an

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.09) per share which beat the analyst c

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibo

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antib